Chugai Pharmaceutical

4519.TPhase 3

chugai-pharm.co.jp

Chugai Pharmaceutical Co., Ltd. is Japan's premier biotechnology company and a subsidiary of Roche, focusing on precision medicine and innovative drug development. Founded in 1925, the company has built a strong portfolio in oncology, autoimmune diseases, and rare conditions through both in-house R&D and strategic partnerships with Roche. Chugai operates as Roche's key development and commercialization hub in Japan while maintaining its independent research capabilities and Tokyo Stock Exchange listing.

Market Cap

$89.4B

Employees

7,000-8,000

Focus

Biotech

4519.T · Stock Price

USD 8650.00+4635.00 (+115.44%)

Historical price data

AI Company Overview

Technology Platform

Advanced antibody engineering platform including POTELLIGENT ADCC enhancement technology and bispecific antibody development capabilities for precision medicine applications.

Pipeline Snapshot

100

100 drugs in pipeline, 57 in Phase 3

Drug	Indication	Stage
Pegasys® + Pegasys®	Chronic Hepatitis C	Approved
Satralizumab 120 mg	Neuromyelitis Optica Spectrum Disorder	Approved
R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placebo	Hemodialysis Patients	Phase 3
R744 + Epoetin beta	Predialysis Patients	Phase 3
MRA(Tocilizumab)	Polyarticular Juvenile Idiopathic Arthritis	Phase 3

Funding History

Total raised: $150M

IPO$150MRocheSep 15, 2002

Opportunities

Chugai is positioned to capitalize on Japan's aging population, growing rare disease markets, and expansion of precision medicine.

The company's unique Roche partnership provides access to global pipeline assets while maintaining independent R&D capabilities for innovative antibody therapies.

Risk Factors

Key risks include patent cliff challenges for major products, intense competition in oncology markets, regulatory uncertainties, and potential conflicts between independent operations and Roche strategic priorities.

Currency fluctuations and healthcare pricing pressures also pose ongoing challenges.

Competitive Landscape

Chugai competes with major Japanese pharma companies like Takeda and Daiichi Sankyo, as well as global players including Pfizer, Bristol Myers Squibb, and Merck. The company differentiates through its Roche partnership, innovative antibody platform, and strong presence in oncology and rare diseases.

Publications

Patents

Pipeline

100